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Metastasis is a multi-step process wherein tumour cells detach from the primary mass, migrate through barrier matrices, gain access to
conduits to disseminate, and subsequently survive and proliferate in an ectopic site. During the initial invasion stage, prostate
carcinoma cells undergo epithelial–mesenchymal-like transition with gain of autocrine signalling and loss of E-cadherin, hallmarks that
appear to enable invasion and dissemination. However, some metastases express E-cadherin, and we found close connections
between prostate carcinoma cells and hepatocytes in a liver microtissue bioreactor. We hypothesise that phenotypic plasticity occurs
late in prostate cancer progression at the site of ectopic seeding. Immunofluorescence staining for E-cadherin in co-cultures of
hepatocytes and DU-145 prostate cancer cells revealed E-cadherin upregulation at peripheral sites of contact by day 2 of co-culture;
E-cadherin expression also increased in PC-3 cells in co-culture. These carcinoma cells bound to hepatocytes in an E-cadherin-
dependent manner. Although the signals by which the hepatocytes elicited E-cadherin expression remain undetermined, it appeared
related to downregulation of epidermal growth factor receptor (EGFR) signalling. Inhibition of autocrine EGFR signalling increased
E-cadherin expression and cell–cell heterotypic adhesion; further, expression of a downregulation-resistant EGFR variant prevented
E-cadherin upregulation. These findings were supported by finding E-cadherin and catenins but not activated EGFR in human prostate
metastases to the liver. We conclude that the term epithelial–mesenchymal transition only summarises the transient downregulation
of E-cadherin for invasion with re-expression of E-cadherin being a physiological consequence of metastatic seeding.
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Metastasis causes the vast majority of the morbidity and mortality
from cancer. However, our understanding of the multi-step
cascade of events that must occur for successful attachment and
subsequent metastasis has not been completely elucidated, as few
systems are available to examine the intermediary dynamic steps
that occur during progression (Condeelis and Segall, 2003; Yates
et al, 2007). Only now are investigators defining the changes
needed for both a cell to escape from the primary tumour and
subsequently to allow for ectopic survival and proliferation.
An essential step for cells to migrate from the primary tumour
mass is the loss of epithelial cell–cell adhesions and subsequent
acquisition of a mesenchymal-like migratory and invasive
phenotype, generally referred to as epithelial–mesenchymal
transition (EMT) (Thiery, 2002; Ackland et al, 2003; Bates and
Mercurio, 2005). Central to this dissociation from the primary
tumour is altered or loss of E-cadherin expression (Davies et al,
2000; Lowy et al, 2002) a key attribute that may define the EMT. E-
cadherin is a calcium (Ca
2þ)-dependent transmembrane cell
surface glycoprotein. E-cadherin rapidly localises on the cell
surface to regions of contact, usually resulting in homotypic cell–
cell binding; this fosters the maintenance of normal cellular
structure. Recently, reports have shown that aberrant loss or
downregulation of E-cadherin in carcinomas may result from
reversible epigenetic events (Graff et al, 1995; Lind et al, 2004) or
growth factor-mediated downregulation (Hurtubise and Momparler,
2004; Wheeler, 2005), suggesting that loss of this tumour
suppressor may be reversible. That this reversal might happen
has been suggested by the findings that secondary tumour
metastases express E-cadherin (Brabletz et al, 2001; Rubin et al,
2001). However, that this expression at the distal site represents re-
expression of E-cadherin has not been demonstrated.
Activation of the epidermal growth factor receptor (EGFR)
downregulates E-cadherin expression (Jawhari et al, 1999; Ackland
et al, 2003). This suggested that autocrine EGFR signalling present
in prostate carcinomas may contribute to E-cadherin repression in
these tumours. This was supported by our recent finding that
pharmacological abrogation of EGFR signalling in prostate
carcinoma cells reverses decreased E-cadherin expression render-
ing these cells less invasive and more cohesive (Jawhari et al, 1999;
Yates et al, 2005). This re-expression of E-cadherin is similarly
observed by close contacts of DU-145 prostate carcinoma cells
when cultured within the liver microenvironment (Yates et al,
2007). As prostate cancer metastasises to the liver in over half of all
patients with metastatic disease (Ewing, 1922; Shah et al, 2004),
we sought to explore the correlative expression levels of EGFR and
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sE-cadherin in the presence of parenchymal cells of the liver. We
show, herein, that hepatocytes elicit E-cadherin expression in
prostate carcinoma cells concomitant with downregulation of
EGFR signalling.
MATERIALS AND METHODS
Materials
The primary antibodies used were mouse monoclonal antibodies
selective for human E-cadherin, human cytokeratin 18 and human-
specific controls tubulin (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). Primary antibodies to phospho-EGFR (Cell Signaling,
Danvers, MA, USA), a-catenin, b-catenin, p120 (BD Biosciences,
San Jose, CA, USA) and vimentin (Dako Laboratories, Carpinteria,
CA, USA). Polyclonal antibody to EGFR was used for immuno-
histochemistry (Santa Cruz). Secondary antibodies for immuno-
fluorescence dyes or horseradish peroxidase-conjugated were
obtained from (Jackson Laboratories, Bar Harbor, ME, USA).
Anti-E-cadherin blocking antibody (SHE78-7) was obtained from
Zymed Laboratories (South San Francisco, CA, USA). The EGFR
inhibitor PD153035 and primary antibody to human EGFR (Ab-1),
were obtained from Calbiochem (San Diego, CA, USA). Other
reagents were obtained from Sigma (St Louis, MO, USA).
Cell lines
The androgen-independent DU-145 and PC-3 human prostate
carcinoma cell line were originally derived from a brain and bone
metastasis of a human prostate adenocarcinoma, respectively. A
transmodulation-resistant EGFR construct was generated by
replacing the PKC-target threonine at amino acid 654 with alanine
(A654) and transfected into DU-145 cells (Yates et al, 2005).
Prostate cancer cells lines were cultured as described previously
(Yates et al, 2005). Red fluorescent protein (RFP) was stably
transfected with ds-Red (Clontech, Mountain View, CA, USA)
vector containing a neomycin resistance gene in DU-145 cells. RFP
expressing cells were selected and maintained in DMEM with 10%
FBS and in the presence of 1000mgml
 1 G418 until used for
experimentation.
Reverse transcription-PCR
Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA,
USA). RT reaction was performed using total RNA as a template
and an RT for PCR kit (Invitrogen). PCR amplification was carried
out with the following primers: human-specific E-cadherin
primers, 50-gacacccgattcaaagtggg-30 and 50-gtctctcttctgtcttctgag-30;
showed no homology to rat E-cadherin and 30.2% homology to
mouse E-cadherin. GAPDH primer kit 50-ccacccatggcaaattccatgg
ca-30 and 50-tctaacggcaggtcaggtccacc-30 (Stratagene, Cedar Creek,
TX, USA) recognises both human and rodent sequences.
Hepatocytes
Primary rat hepatocytes, 490% purified, were obtained by
collagenase perfusion (Seglen, 1976) of 150–230g male eGFP
(enhanced green fluorescent protein)-transgenic and WT (wild-
type) Sprague–Dawley rats, originally generated by Dr Masaru
Okabe (Genome Information Research Center, University of
Osaka, Osaka, Japan) and were generously provided by Japan
SLC, Inc. (Hamamatsu, Japan). Use of rat hepatocytes enables the
identification of the human prostate carcinoma cell proteins using
human-specific antibodies. The cells were collected and main-
tained in Hepatocyte Growth Media (HGM) medium before and
during co-culture (Yates et al, 2007). These studies were approved
by the University of Pittsburgh IACUC committee.
Co-cultures
Initial co-cultures consisted of 50000cellscm
 2 of freshly isolated
hepatocytes and 2000cellscm
 2 prostate cancer cells. Co-cultures
were maintained in serum-free HGM (Yates et al, 2007), and plated
on tissue culture dishes pre-treated with 10% collagen (Upstate,
Charlottesville, VA, USA).
Centrifugal assay for cell adhesion
This assay is a modification of the McClay and Giacolmello assays
(McClay et al, 1981). Cancer cells were non-enzymatically
dissociated and labelled with 5mM Calcein AM (Molecular Probes,
Carlsbad, CA, USA). Labelled cancer cells were seeded at a density
of 42000cellswell
 1 in 96-well plates containing a densely
confluent hepatocyte monolayer. The plates were centrifuged for
o60s at 50g to pellet the cancer cells onto the hepatic monolayer,
then incubated at 371C. At defined times, the plates were
inverted and centrifuged at 600g for 5min and then gently washed
to remove unbound cells from the hepatocyte monolayer.
Fluorescence was measured with a 494/517 bandpass filter set-up
from the bottom of the plate by a TECAN Spectra-Fluor plate
fluorometer. Absolute emission measurements were background
subtracted.
Tissue specimens
Formalin-fixed paraffin-embedded tissues were obtained from the
University of Pittsburgh Tumor Bank. We found only two well-
defined prostate adenocarcinomas with liver metastases and none
from the Cooperative Human Tumor Network, irrespective of
other criteria. These studies, blinded for all personal identifiers,
were categorised as exemption 4e by the University of Pittsburgh
IRB.
Statistical analysis
Statistics for all experiments were performed using the Sigma Plot
statistical program (Jandel Scientific, Chicago, IL, USA). Indepen-
dent Student’s t-test was utilised to determine a statistical
difference between experimental and the controls for individual
experiments, with significance generally informed at Po0.05.
RESULTS
E-cadherin is generally lost from the primary tumour cells of
metastatic carcinomas, with the result that these cells can now
detach from the primary tumour mass and attain a nonpolarised,
migratory phenotype (Bates and Mercurio, 2005). Unlike many
other tumour suppressors, the E-cadherin gene is neither deleted
nor mutated, but rather the downregulation appears to result from
epigenetic signals, opening the possibility that this loss of
expression may be reverted later during the metastatic cascade
(Yates et al, 2007). Intriguingly, E-cadherin expression has been
noted on metastases of human carcinomas (Rubin et al, 2001).
Thus, we proposed that E-cadherin re-expression coincided with
distant metastases, enabling the prostate carcinoma cells to
interact with the ectopic parenchyma (Yates et al, 2007). We
tested this postulate using liver hepatocytes, as liver is the
epithelial organ most commonly colonised by metastatic prostate
carcinoma (Ewing, 1922; Shah et al, 2004).
We found that co-culturing DU-145 and PC-3 carcinoma cells
with rat hepatocytes resulted in increased E-cadherin expression
and decreased EGFR expression (Figure 1A). This occurred
over a 6-day period in both cell types, with significant differences
by day 2 (Figure 1A and B). The increase in E-cadherin
protein levels was reflected by similarly elevated mRNA levels
(Figure 1B), though the appearance of mRNA may lag by about
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at protein degradation and the other at de novo transcriptional
potential.
Since loss of E-cadherin and increased EGFR signalling are
known markers of invasive mesenchymal cancer cells (Wong and
Gumbiner, 2003), we asked if the E-cadherin re-expression and
EGFR decreases were accompanied with another known epithelial
cell marker. Cytokeratin 18 expression, a marker of mature
epithelial cells, increased over the 6-day period in both DU-145
and PC-3 cell lines suggesting a reversion of mesenchymal
phenotype characteristic of these cell lines (Figure 1A). This
implied a generalised reversion to a more differentiated phenotype
in the presence of hepatocytes.
Looking more closely at the subcellular localisation of this E-
cadherin and EGFR expression, freshly isolated GFP-expressing
primary rat hepatocytes were allowed to adhere 24h before seeding
of the RFP-expressing prostate cancer cells. As expected,
immunofluorescence showed increases in E-cadherin and b-
catenin and inversely related decreases in EGFR expression in
the presence of hepatocytes. Unexpectedly however, early co-
cultures revealed E-cadherin expression at the prostate cancer cell
periphery juxtaposed to the hepatocytes during attachment (Figure
2A and B). b-Catenin was also localised to the membrane area in
these cells further suggesting a functional E-cadherin linkage at the
interface of these two cell types. To our knowledge, E-cadherin
interaction among different cell types has not been noted
previously, thus we consider these interactions as potentially
heterotypic in terms of cell types. While various other proteins
(e.g. selectins and integrins) have been implicated in carcinoma
attachment, heterotypic cell–cell interaction via E-cadherin has
not. Therefore, the ability of prostate cancer cells to utilise E-
cadherin to bind to hepatocytes was tested by assessing cell–cell
adhesion between adherent hepatocytes and prostate carcinoma
cells using the centrifugal assay for cell adhesion (McClay et al,
1981). Both DU-145 and PC-3 cells, calcein-AM-labelled, bound to
the hepatocytes to a limited but statistically significant degree, and
this binding was eliminated by an E-cadherin blocking antibody
(Figure 3A–E). As the cell–cell adhesion of the prostate carcinoma
cells was limited, though real, we sought to increase the levels of E-
cadherin on these cells. For this we used the EGFR kinase inhibitor,
PD153035, that we had shown earlier to promote E-cadherin
expression in DU-145 cells within 24–48h (Yates et al, 2005), and
confirmed in PC-3 cells at 48h (Figure 3C). This 48-h pretreatment
with PD153035 increased prostate carcinoma cell binding to the
hepatocyte monolayer (Figure 3A–E).
The above findings implicate EGFR signalling as potentially
negatively regulating E-cadherin levels. As this was reminiscent of
the situation with LHRH receptor transmodulation of autocrine
EGFR signalling in DU-145 cells (Yates et al, 2005), we asked
whether a similar situation might be functioning in this setting. We
expressed the PKC transmodulation-resistant EGFR A654 variant
(Welsh et al, 1991) in the DU-145 cells. Co-culturing these cells
with hepatocytes did not lead to decreases in EGFR or increases in
E-cadherin and cytokeratin 18 expression (Figure 4). If anything,
the DU-145 A654 cells exhibited a decrease in E-cadherin
expression over 6-day period, which would be expected since
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Figure 1 Co-culture of human prostate cancer cell with rat hepatocytes reversed E-cadherin expression. DU-145 or PC-3 (A) cells were co-cultured in
the presence of primary rat hepatocytes over a 6-day period. Hepatocytes and single cultures were lysed before co-cultures. On days 1, 2, 4 and 6, co-
culture lysates were immunoblotted with indicated human selective antibodies: anti-E-cadherin, anti-EGFR antibody, anti-cytokeratin 18 and anti-tubulin (as
the loading control). (B) Densitometry of immunoblots in DU-145 and PC-3 cells co-cultures (’) EGFR, (&) E-cadherin () and Cytokeratin 18; shown are
the mean7s.d. of three blots with day 0 being at 100 (*Po0.05 from C0). Cellular levels of E-cadherin mRNA in DU-145 or PC-3 (C) cells were analysed
by RT-PCR using GAPDH as a loading control. In A and B, Co (for control) are an equal number of prostate carcinoma cells incubated for 1 day in the
absence of hepatocytes. The Hep (hepatocytes) were an equal number of hepatocytes as for the co-cultures. The first three lanes were all lysed at the same
time. Shown are representative of at least three experiments.
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documented as leading to E-cadherin downregulation.
These data present a potential metastatic target organ-specific
regulation of prostate carcinoma cell phenotype. However, to
validate whether this may occur in de novo human tumours, we
obtained human liver tissue from two patients with prostate cancer
metastases to the liver and examined the expression of E-cadherin
in these tumours by immunohistochemistry. E-cadherin staining
was significant in the tumour nodules within the liver (Figure 5A).
This increased expression was accompanied by increases in E-
cadherin-associated adhesion molecules a, b and p120 catenin as
well (Figure 5A). Central to our model of inverse relationship
between E-cadherin expression and EGFR (Yates et al, 2005), we
were able to observe a lack of total and active EGFR expression in
these tumours (Figure 6A). To molecularly determine if these
tumours reverted to a more epithelial phenotype, we stained for
the epithelial marker cytokeratin 18 and the mesenchymal marker
vimentin. Akin to our in vitro findings, these tumours largely
express cytokeratin and lack vimentin expression (Figure 6B). In
the absence of the primary tumours, from which these metastases
derived, we cannot state that this represents a reversion in the
phenotypic profile, but given the widespread finding of EMT in
invasive and metastatic primary tumour, it does suggest that there
may be cancer cell phenotypic variability as result of the metastatic
microenvironment.
DISCUSSION
Loss of E-cadherin is so widely observed in advanced carcinomas
that the E-cadherin molecule is considered a tumour suppressor
(Wong and Gumbiner, 2003). This conception of E-cadherin is
supported by forced re-expression of E-cadherin resulting in
diminished tumourigenic potential in experimental tumour
systems (Jawhari et al, 1999; Yates et al, 2005). However, unlike
classical tumour suppressors (e.g. p53 and Rb), E-cadherin loss
occurs by epigenetic downregulation or transcriptional silencing,
rather than genetic deletion or mutation (Graff et al, 1995). As the
Control Day 3 Day 6
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Figure 2 Immunofluorescence of co-cultures show subcellular location of E-cadherin re-expression. (A) Immunofluorescence of DU-145 RFP (red) and
GFP (green) primary rat hepatocytes were stained with human-specific anti-E-cadherin, pan-species anti-b-catenin or human-specific anti-EGFR antibody.
Cy5 secondary antibody (blue) was used for respective primary antibodies. Note the gain of blue (E-cadherin) in the RFP/red prostate cells in the top and
middle rows, and the loss of blue (EGFR) in the bottom row. (B) The blue channel only of the lower left inset in the E-cadherin and b-catenin staining on day
2 is shown in black and white to demonstrate the localisation of the human E-cadherin in the prostate carcinoma cells to the interface with the hepatocytes.
In the middle row, the hepatocytes were from WT and not GFP rats, so as not to interfere with the antibody staining as the anti-b-catenin detected both
human and rat. However, the presence of b-catenin upregulation in the DU-145 cells is noted by a violet color and the membranous pattern at the
hepatocyte–prostate carcinoma cell interface. Shown are representative of at least three experiments.
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the question as to whether there are situations in which re-
expression of E-cadherin and subsequent cell–cell adhesion may
promote tumour progression. Herein, we provide proof of
principle that parenchymal cells from a tissue frequently targeted
for prostate carcinoma metastasis, the liver (Ewing, 1922; Lind
et al, 2004; Shah et al, 2004), signal this re-expression of E-
cadherin.
Downregulation of E-cadherin occurs frequently in the primary
prostate tumour coincident with aggression and spread (Gingrich
et al, 1996; Kallakury et al, 2001). However, expression in distant
metastases has been noted in some prostate cancer metastases
(Rubin et al, 2001) but not in other studies in metastases to the
bone (Bryden et al, 2002). Our findings herein, appear consistent
with the re-expression, though the liver environment is likely
substantially different from that of the bone in terms of signals to
the hepatocytes and requirements by the metastatic tumour cells.
It must also be noted that there is precedence for E-cadherin
expression on disseminated carcinomas, as ovarian carcinoma
dissemination throughout the peritoneal cavity shows increased
levels of E-cadherin and its attendant catenins (Imai et al, 2004).
Again, though, the applicability to metastatic spread of an organ-
confined prostate cancer to a distant-defined organ compartment
may not be comparable to the spread of ovarian carcinoma
throughout an adjacent open cavity.
The findings herein raise two questions that need to be explored
in depth in future investigations. First and most obvious, the
mechanism by which the hepatocytes signal for E-cadherin re-
expression needs to be defined. Our initial findings strongly
suggest a link to downregulation of autocrine EGFR signalling.
EGFR levels change inversely to the E-cadherin levels, and direct
inhibition of EGFR signalling leads to increased E-cadherin
expression (Yates et al, 2005). More directly, expression of an
EGFR variant that is resistant to PKC-mediated attenuation
renders the DU-145 cells impervious to hepatocyte-induced E-
cadherin expression. This presages the ultimate issues of the
nature of the signals from the hepatocytes and which carcinoma
intracellular processes actuate the E-cadherin re-emergence. The
intracellular events may be complex and involve both loss of
downregulation at the protein level and reversion of transcrip-
tional suppression. That EGFR activity is known to disrupt the
E-cadherin/catenin complex leading to E-cadherin protein destabi-
lisation and degradation (Ackland et al, 2003) and the impression
that E-cadherin protein expression may precede increased mRNA
suggest that protein downregulation is part of the answer.
Although the intracellular mechanisms of E-cadherin re-expres-
sion are undoubtedly complex, these findings are novel and
provide insight of prostate cancer cell behavior within a target soft
organ.
One caveat that deserves specific mention is that EGFR
signalling contributes to numerous aspects of prostate tumour
progression. For instance, autocrine EGFR-mediated motility
promotes tumour invasion and metastasis and tumour cell
proliferation and survival (Wells, 2000). Thus, targeting EGFR
kinase may have effects other than promoting the metastatic
engraftment proposed herein by the upregulation of E-cadherin.
For instance, the recent report of EGFR kinase inhibitors limiting
prostate tumour dissemination in experimental models (Angelucci
et al, 2006) is likely due to inhibiting pathways and cell behaviors
before the proposed upregulation of E-cadherin at the metastatic
site, though re-expression of E-cadherin at the primary tumour site
would also limit spread by preventing initial detachment (Jawhari
et al, 1999; Lowy et al, 2002; Wong and Gumbiner, 2003).
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Figure 3 Human prostate cancer cells form E-cadherin-mediated heterotypic interactions with hepatocytes. DU-145 (A and B) cells or PC-3 (C–E) cells
fluorescently labelled with Calcein A were incubated for 48h with PD153035 or E-cadherin blocking antibody and seeded onto a monolayer of hepatocytes
from non-GFP-expressing rats to analyse their ability to adhere. Cell binding was assessed by fluorescent intensity using a plate fluorometer and visually
verified under a fluorescent light microscope. Y-axis is arbitrary fluorescent units. Data represent mean of three experiments performed in triplicate; s.e.
*Po0.05. Shown are sample representative fields to show the bound tumour cells (converted to white dots) overlying the hepatocytes in B and E.( C) PC-
3 cells were exposed to PD153035 for 48h with a resultant upregulation of E-cadherin as shown by immunoblotting. This is similar to our previously
published finding with DU145 cells (Yates et al, 2005).
Hep Co D1 D2 D4 D6
EGFR
E-cadherin
Cytokeratin 18
Tubulin
Figure 4 DU-145 cells expressing a PKC transattenuation-resistant
EGFR (A654) are resistant to hepatocyte-induced E-cadherin re-expres-
sion. DU-145 A654 cells co-culture lysates were immunoblotted with an
antibody selective for human E-cadherin, EGFR, cytokeratin 18 or tubulin.
The legend is as with Figure 1, Co (control) DU145 A654 cells and Hep
(hepatocytes) only. Shown is one of two representative blot series.
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E-cadherin re-expression remains in the speculative realm. Our
finding and those reported in the literature (Rubin et al, 2001;
Kowalski et al, 2003) or carcinoma metastases presenting E-
cadherin and differentiation-related cytokeratins, along with low
to absent levels of vimentin and EGFR (total and active), cannot
discern whether these metastases arose from a subset of primary
tumour cells that never underwent a phenotypic shift or from the
majority of aggressive cells that underwent the so-called epithe-
lial–mesenchymal transition. However, the fact that experimental
prostate cancer cell lines, DU-145 and PC-3, exhibited similar
phenotypic shifts when cultured with hepatocytes implies a
survival or growth advantage in these ectopic sites that is at odds
with that seen for the EMT tumour cells in the primary locale.
Recently, this has been supported experimentally by the finding
that epithelial variants of a bladder carcinoma cell line presented
Control E-cadherin E-cadherin
p120 -catenin -catenin
Figure 5 Human prostate cancer metastases to liver show expression of cell–cell adhesion molecules. Formalin-fixed, paraffin-embedded tissues were
obtained from two well-defined prostate adenocarcinomas with liver metastasis. Tissues were stained with indicated antibodies, Secondary antibody, anti-
mouse only as the staining control (top left; 3700mm
2), anti-E-cadherin (top centre; 3700mm
2 and top right; 300mm
2), anti-a-catenin (bottom right;
300mm
2), anti-b-catenin (bottom centre; 300mm
2) and anti-p120 (bottom right; 300mm
2). Shown are representative of repeated stainings; the other
metastasis presented similar findings.
Control EGFR
Cytokeratin 18 Vimentin
pEGFR
Figure 6 Human prostate cancer metastases show reversion of metastatic markers. Tissues were stained with anti-rabbit (top left; 1400mm
2) anti-EGFR
(top centre; 1400mm
2), anti-phosphotyrosyl-EGFR (activated EGFR) (top right; 1400mm
2), anti-vimentin (bottom left; 1400mm
2) and anti-cytokeratin 18
(bottom left; 1400mm
2). Shown are representative of repeated stainings; the other metastasis presented similar findings.
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circulation than the mesenchymal parental line, whereas the
parental mesenchymal tumour line possessed increased metastatic
capabilities from an orthotopic location (Chaffer et al, 2006). One
can speculate that in a metastatic tumour microenvironment
lacking many of the prostate-specific survival signals, E-cadherin-
mediated linkages provide critical survival signals, by linking to
both other carcinoma cells and even the hepatocytes themselves.
Such studies, which lie beyond the realm of the current
communication, are underway.
In conclusion, we propose a model in which the differentiation
phenotype of metastatic prostate carcinoma cells is plastic in
response to the microenvironment. In the primary tumour setting,
E-cadherin expression is downregulated as part of the EMT
that allows disaggregation from the primary mass enabling
invasive migration and distant dissemination. However, once the
tumour cells reach the ectopic microenvironment, numerous
signals critical for survival and/or growth are absent. The
metastatically competent subset of tumour cells interpret initiating
signals from the target organ, in this case the liver, to re-express
a more differentiated phenotype, or to undergo a mesenchymal–
epithelial reverse transition. This redifferentiation could
provide for both homotypic and heterotypic cell–cell adhesion
with concomitant survival signals. While such a redifferentiation
would be expected to limit tumour cell proliferation and local
invasiveness, it may be key to prevent tumour cell apoptosis
in the absence of a supportive orthotopic microenvironment.
In-depth exploration is necessary not only to determine if such
metastatic carcinoma redifferentiation occurs in de novo metas-
tasis of human tumours, but also to explain the relative resistance
to chemotherapy of metastases and even the concept of tumour
dormancy.
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